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Abstract
Background: Kidney allograft resistive index (RI) is prognostic for graft and recipient survivals. Recipient hemodynamics
could influence RI. In particular, dialysis arteriovenous fistula (AVF) has been involved in heart function changes, reversible
after AVF ligation. Knowledge about AVF and RI is lacking. In this study, we prospectively evaluated RI changes after AVF
ligation in kidney transplanted patients.
Methods:We enrolled 22 stable transplanted patients. Mean RI was measured before AVF ligation (T0), 18 to 24 h (T1)
and 6 months (T6) after surgery; mean blood pressure (mBP), heart rate (HR), serum creatinine (sCr), estimated glo-
merular filtration rate (eGFR), 24 h proteinuria (24 h-P), immunosuppressive drug blood levels (IS) and antihypertensive
drugs were also recorded.
Results: AVF ligation was performed 3.1 years (IQR: 2.1–3.8) after transplantation. Median AVF flow (Qa) was 1868 mL/
min (IQR: 1538–2712) and 8 AVF were classified as high flow (Qa  2 L/min). At baseline, median sCr was 1.32 mg/dL
(IQR: 1.04–1.76) and median eGFR was 57.1 mL/min. Median RI was 0.71 at T0, 0.69 at T1, 0.66 at T6. RI reduction at T1
and T6 was statistically significant (p < 0.05 and p < 0.001 respectively); in particular, 90.4% of patients had persistently
improved values at T6. Furthermore, mBP increased while HR decreased. These changes were independent from sCr, 24
h-P, IS, antihypertensive drugs number, Qa and AVF type.
Conclusions: AVF ligation improves kidney allograft RI; it may reflect better kidney perfusion.
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Introduction
Arteriovenous fistula (AVF) is the preferred vascular
access for hemodialysis since it associates with improved
treatment efficacy and reduced infection risk than central
venous catheter (CVC).1 However, AVF creation affects
systemic hemodynamics by reducing peripheral vascular
resistance and by increasing heart venous return. Left ven-
tricular hypertrophy, left ventricular diameters, and cardiac
index increase, bi-atrial dilatation, tricuspid annular plane
systolic excursion (TAPSE) decrease, cardiac oxygen supply
and demand changes, atrial natriuretic peptide (ANP) and
brain natriuretic peptide (BNP) increased secretion are
reported.2–5 Different authors reported greater hemodynamic
impact due to high-flowAVF (Qa 2 L/min) and they high-
light the risk of heart failure, myocardial infarction, and lung
hypertension.6,3
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In kidney transplant (KT) patients, changes of these
heart morpho-functional alterations are reported after
spontaneous or surgical AVF closure.7–9 Recently, Rao
et al.10 demonstrated that AVF ligation in adults with stable
KT function resulted in significant reduction of left ven-
tricular myocardial mass and improved clinical heart per-
formance. However, routine AVF ligation after KT is not
recommended as it is not clear whether the benefits out-
weigh the risk of restarting dialysis without an appropriate
vascular access.11,12 To date, the most common reasons for
AVF ligation are heart failure, high-flow fistula, local com-
plications, and aesthetic.13 Conversely, little is known
about AVF impact on peripheral tissue perfusion and in
particular on kidney graft.14
Kidney allograft RI is an indirect and dynamic marker
of intrarenal vascular perfusion.15,16 RI is calculated by
Doppler ultrasound measure of blood speed within the arci-
form renal arteries; higher RI corresponds to increased
resistance.17 Initially, RI was considered as marker of
intrarenal vascular injury; more recently it has been
demonstrated that RI is also influenced by aortic vascular
compliance and cardiac function.18–20 Other factors influ-
encing RI in KT are sex, body weight, height, and KT
recipient age.21
Several studies reported RI evaluations as prognostic
factor for long-term KT function, allograft and recipient
survival, and both cardiovascular morbidity and mortal-
ity.22–28 We herein hypothesized that AVF ligation induces
RI changes related to hemodynamics variation; thus, we
prospectively measured RI in a cohort of KT patients
before and after AVF ligation.
Methods
We recruited all consecutives patients with stable KT func-
tion who underwent AVF ligation between April 2016 and
February 2017 in AOU Citta` della Salute e della Scienza—
Presidio Molinette, Turin. An internal commission
approved the study protocol and the investigation was per-
formed in accordance with the Helsinki declaration.
Two certificated experience in vascular ultrasound
nephrologists independently performed AVF flow (Qa)
Doppler measurement. AVF flow was calculated at the
humeral artery. In particular, Qa was measured with a
LA523 4.5 to 11.5 MHz linear probe (MyLabFive, Esaote).
AVF ligation was performed by vascular surgical team
with local or plessic anesthesia.
RI was assessed the day before AVF surgical closure
(T0), 18 to 24 h (T1) and 6 months (T6) after surgery.
Operators were blinded on AVF blood flow and previous
RI results. Kidney interlobular arteries were evaluated by a
CA621 3.5 to 8 MHz convex probe (MyLabFive, Esaote)
and the RI was calculated with the formula: ((peak systolic
velocity – end diastolic velocity)/peak systolic velocity).
Three measurements were obtained (lower pole, between
poles, and upper pole) and mean values were included in
the statistical analysis. At the same time points, we also
collected laboratory values, vital parameters, and drugs
anamnesis. Collected variables were: serum creatinine
(sCr), 24 h proteinuria (24 h-P), immunosuppressive blood
levels (IS), estimated glomerular filtration rate (eGFR—
calculated according to the chronic kidney disease epide-
miology collaboration equation), HR, and mean blood
pressure (mBP). Medication anamnesis included all drugs
taken by patients, with particular attention to antihyperten-
sive agents. All data were collected prospectively.
Statistical analysis
Statistical analysis was performed with SPSS (IBM SPSS
Statistics, vers. 25.0.0). Continuous variables are described
by median and interquartile range (IQR), according to their
non-Gaussian distribution, and were analyzed with
Kolmogorov-Smirnov test. Within-patient comparison was
performed and the differences were analyzed with Mann-
Whitney or Wilcoxon test. Categorical variables are pre-
sented as fraction and Pearson’s 2 or Fisher’s exact test
were used to compare data. Significance level for all tests
was set at a < 0.05. Simple linear regression approach was
employed to analyze the relationship between independent
variables.
Results
We enrolled twenty-three patients with stable graft func-
tion and functioning AVF. One of them experienced severe
acute interstitial rejection and restarted dialysis. Twenty-
two patients completed the study with valid data. Table 1
reports baseline characteristics of our population. Median
age was 60 years and 73% of patients were male. Nobody
had a dual KT; one patient had a combined pancreas-KT
and another a liver-KT. Two patients had a second KT.
AVF ligation was performed after a median of 3.1 years
from transplant (IQR: 2.1–3.8).
Median AVF survival was 7.1 years (IQR: 4.2–9.6). In
all, 41%was brachiocephalic AVF, 54.5%was radiocepha-
lic AVF at the forearm, 4.5% was brachial–basilic arterio-
venous graft. Median Qa was 1868 mL/min (IQR: 1538–
2712); 8/22 AVF were classified as high flow (Qa  2 L/
min). The most frequent kidney disease resulted to be
Autosomal Dominant Polycystic Disease (ADPKD)
(36.4%). Twenty-one patients used calcineurin inhibitors
(CNi) as immune suppressant: tacrolimus in 19/21 cases,
cyclosporine in 2/21. About half of patients had cardiac
hypertrophy, only one had a left ventricular hypokinesia
and 18.2% had a previous ischemic event (coronary acute
syndrome or inducible ischemia to myocardial scintigra-
phy). Lung hypertension has been detected in 35.7% of
patients (defined as estimated pulmonary artery pressure
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systolic over 25 mmHg). Table 2 reports baseline donor
characteristics.
In high-flow AVF the reason for surgical ligation was
heart failure risk; in the others cases patients required liga-
tion due to aesthetic reasons or local complications (aneur-
ysm). No major surgical complications (i.e. bleeding or
hemodynamic instability) were recorded during the proce-
dure. Two patients needed re-surgery to drain hematoma,
both at 6 days after ligation. No infections were recorded.
In Figure 1, RI values, vital parameters, and laboratory
exams recorded at three time points (T0–T1–T6) are
reported.
Median RI was 0.71 (IQR: 0.66–0.74) at T0, 0.69
(IQR: 0.63–0.72) at T1, 0.66 (IQR: 0.61–0.69) at T6. RI
changes from T0 to T1 and from T0 to T6 were statisti-
cally significant (p ¼ 0.034 and p < 0.001 respectively—
Figure 1). RI was reduced from T0 to T6 in 90.4% of
cases, unchanged in only one case (4.8%) and increased
in another one (4.8%). T0 to T6 median RI decrease was
0.04 (0.01 – 0.09).
Furthermore, median HR significantly decreased from
T0 to T1 (from 68 to 64 bpm; p ¼ 0.004) and median mBP
significantly increased from T0 to T6 (from 98 to 105
mmHg; p < 0.05).
No significant changes in renal function (sCr, eGFR or
24 h-P) were observed at T6; median sCR was 1.33 mg/dL
(IQR: 1.04–1.76) at T0, 1.32 mg/dL (IQR: 1.03–1.84) at
T1, and 1.35 mg/dL (IQR: 1.15–1.72) at T6; median eGFR
was 57.1 mL/min (IQR: 35.7–73.0) at T0, 57.1 mL/min
(IQR: 32.7–72.5) at T1, and 55 mL/min (IQR: 37.7–73.2)
at T6; 24 h-P was 0.166 gr/24 h (IQR: 0.10–0.23) at T0,
0.19 gr/24 h (IQR: 0.11–0.23) at T1, and 0.18 gr/24 h (IQR:
0.09–0.38) at T6.
Immunosuppressive regimen was unchanged in all but
one case in which mycophenolate mofetil was added.
Tacrolimus through levels were unchanged.
No correlation was found with tacrolimus blood levels
and RI. No correlation was investigated for cyclosporine,
due to the limited patient number. Antihypertensive ther-
apy remained unchanged from T0 to T6; patients used an
average of two antihypertensive drugs at each time. No
correlation between AVF flow before ligation and changes
in RI was seen, nor ligation of high-flow AVF was asso-
ciated with larger RI drop. No cardiac events were
recorded in the follow-up.
Discussion
AVF surgical ligation after KT is controversial. No defini-
tive evidences are available and the procedure is not rec-
ommended in asymptomatic patients.12 Different studies
recorded echocardiographic improvements after AVF clo-
sure,7–10 while some authors have reported a blood pres-
sure raise.14
Kidney RI is a prognostic index for cardiovascular mor-
bidity and mortality and for KT survival.22–28 RI is
Table 1. Baseline characteristics of studied population.
Characteristics Value
Gender male—%; (n) 73 (16/22)
Age in years—median value; (IQR: 25–75) 60 (50–70)
Transplant vintage in years—median value;
(IQR: 25–75)
3.1 (2.1–3.8)
Single transplant—%; (n) 100 (22/22)
Pancreas-KT—%;(n) 4.5 (1/22)
Liver-KT—%;(n) 4.5 (1/22)
Second KT—%;(n) 9 (2/22)
AVF vintage age in years—median value;
(25–75)
7.1 (4.2–9.6)
Brachiocephalic AVF—%; (n) 41.0 (9/22)
Radiocephalic AVF—%; (n) 54.5 (12/22)
Brachial—basilic graft—%; (n) 4.5 (1/22)
Qa AVF mL/min—median value;
(IQR: 25–75)
1868 (1538–2712)
Qa  2 L/min—%; (n) 36.4 (8/22)
Kidney disease
ADPKD—%; (n) 36.4 (8/22)
ESRD Unknown– %; (n) 22.7 (5/22)
IgA GN– %; (n) 13.7 (3/22)
IgM GN– %; (n) 4.5 (1/22)
Diabetic GS– %; (n) 4.5 (1/22)
MGN—%; (n) 4.5 (1/22)
SLE—%; (n) 4.5 (1/22)
Nephroangiosclerosis—%; (n) 4.5 (1/22)
CNi toxicity– %; (n) 4.5 (1/22)
Immunosuppression regimen with CNi 95.5 (21/22)
TAC– %; (n) 90.5 (19/21)
CyA– %; (n) 9.5 (2/21)
Immunosuppression regimen without
CNi—%; (n)
4.5 (1/22)
Heart features
Cardiac hypertrophy– %; (n) 52.4 (11/21)
Left ventricular hypokinesia—%; (n) 4.8 (1/21)
Ischemic event—%; (n) 18.2 (4/22)
Lung hypertension (PAPs > 25 mmHg)
—%; (n)
35.7 (5/14)
AVF: Arteriovenous fistula. Qa: AVF blood flow. ADPKD: Autosomal
Dominant Polycystic Disease. ESRD: end stage renal disease. IgA GN: IgA
glomerulonephritis. IgM GN: IgM glomerulonephritis. Diabetic GS: dia-
betic glomerulosclerosis. MGN: membranous glomerulonephritis. LES:
systemic lupus erythematosus. CNi: calcineurin inhibitors; TAC: tacroli-
mus; CyA: cyclosporin A. PAPs: pulmonary artery pressure systolic
Table 2. Donors characteristics.
Characteristics Value
Gender male —%; (n) 36.4 (8/22)
Age in years—median value; (IQR: 25–75) 56 (45–67)
Donor sCr in mg/dL– median value; (IQR:
25–75)
0.71 (0.4–0.87)
Donor eGFR with Cockcroft–Gault formula
mL/min—median value; (IQR: 25–75)
102 (65–148)
sCr: serum creatinine. eGFR estimated glomerular filtration rate.
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influenced by a complex balance between renal and sys-
temic hemodynamics. However, it is a reliable marker of
parenchymal perfusion. In this study we hypothesized that
the hemodynamic impact of AVF ligation could affect RI
and thus renal blood flow.
Only one study assessed the impact of AVF closure on
RI but the authors performed a temporary manual compres-
sion; thus, no follow-up data were reported.28 The study
demonstrated a significant decline in renal graft RI during
AVF compression, and the drop was higher after the occlu-
sion of accesses with higher Qa.
In our study, we prospectively measured RI in grafted
kidneys before AVF ligation, 18 to 24 h and 6 months after
the surgery. We observed a progressive RI decrease with
the lowest values recorded at 6 months. Median magnitude
of reduction was 0.04 (IQR: 0.01–0.09) and this occurred
in 90.4% of cases. Higher reduction observed at T6 than at
T1 could be related to a chronic adaptation mechanism.
This data demonstrates the renal hemodynamic impact
induced by AVF closure and may highlight a clinical ben-
efit in selected patients. Of note, no correlation between
AVF flow before ligation and changes in RI was seen (data
not shown), nor higher RI decrease in high-flow AVF,
possibly as a consequence of the relatively high and homo-
geneous Qa values (median was > 1.8 L/min) in our cohort
or the small number of strictly high-flow AVF (defined as
Qa > 2.0 L/min). In addition, RI changes were independent
from the AVF type.
Naesens et al.27 observed that allograft recipients with a
RI of at least 0.80 had higher mortality than those with a RI
of less than 0.80 at 3, 12, and 24 months after transplanta-
tion. At protocol-specified biopsy time points, the RI was
not associated with renal allograft histologic features. So,
they conclude that the RI after transplantation reflects char-
acteristics of the recipient but not those of the graft.
In our study RI was in almost all patients below 0.8,
probably due to patient selection for AVF ligation. Only
stable graft function patients were admitted for AVF liga-
tion. It could be interesting to study the RI modifications
and their clinical impact after AVF ligation in a basal RI
more than 0.8 population.
Relation about RI reduction and graft function long-
term improvement could be supposed, speculating on an
amelioration in allograft perfusion and vascular resis-
tances. In our experience, 24 months after AVF ligation,
sCr and 24 h proteinuria were stable (data not shown). We
could not detect any functional improvement, possibly
because of the relatively small patient sample. In addition,
3.1 years interval between AVF ligation and transplanta-
tion could be a suboptimal timing to significantly impact
on the allograft outcomes; at last, the high frequency of
kidneys from extended criteria donors29 could influence
this observation. In literature, the possibility of renal func-
tion improvement after AVF ligation is debated; Vajdic
et al.30 observed improved eGFR after the procedure, while
other authors did not.31,32
Consistently with the literature, we observed a mBP
increase and HR decrease, probably related to peripheral
vascular resistances rise.14 Not all authors confirm this
observation. In a recent RCT by Rao et al,10 no effect of
AVF ligation on blood pressure was observed. In our
cohort, no significant correlation between RI reduction and
mBP or HR changes was seen. This could be explained by
the relatively small patient number or by the plethora of
Figure 1. Results observed in the studied population.
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physiological mechanisms regulating both mBP and RI; for
instance, an improved kidney perfusion could lead to
reduced angiotensin release.
Of note, antihypertensive therapy remained unchanged
from T0 to T6; so, hypertension at T6 was not treated
aggressively, failing the transplant guidelines recommen-
dations aiming for a lower target blood pressure value. This
observation reflects a “real life” situation: our center per-
forms KT in patients coming from all parts of Italy; there-
fore, our sample included people distributed in many
nephrologist centers; the medical treatments, except for
immunosuppressive regimen, are managed by local
nephrologists after patient discharging. More attention to
the pressure management could be advocated in our
indications.
At last, RI improvement after AVF ligation could add
new elements in AVF closure decision after KT.
To our knowledge, our study is the first one to analyze
prospectively the impact of AVF ligation on KT hemody-
namics. A significant RI decrease was observed and per-
sisted in 90.4% of cases after six months from the
procedure. The small number of patients and the absence
of a control group are the main limitations of this study. A
power analysis prior to the study was not performed and the
study is probably underpowered, in view of the variation in
AVF flow and large numbers of variables that are included
in the analysis. Further studies with larger samples are
needed to prevent these limitations and to assess the
long-term clinical outcomes. Furthermore, the relation
between RI and spleen resistive index could be studied as
a systemic hemodynamic marker.33–35
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